Cargando…

Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures

Solid organ transplantation offers life-saving treatment for patients with end-organ dysfunction. Patient survival and quality of life have improved over the past few decades as a result of pharmacological development, expansion of the donor pool, technological advances and standardization of practi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarzenbach, Marlene, Bernhard, Flavia Elena, Czerlau, Cecilia, Sidler, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290999/
https://www.ncbi.nlm.nih.gov/pubmed/34316450
http://dx.doi.org/10.5500/wjt.v11.i7.254
_version_ 1783724562189385728
author Schwarzenbach, Marlene
Bernhard, Flavia Elena
Czerlau, Cecilia
Sidler, Daniel
author_facet Schwarzenbach, Marlene
Bernhard, Flavia Elena
Czerlau, Cecilia
Sidler, Daniel
author_sort Schwarzenbach, Marlene
collection PubMed
description Solid organ transplantation offers life-saving treatment for patients with end-organ dysfunction. Patient survival and quality of life have improved over the past few decades as a result of pharmacological development, expansion of the donor pool, technological advances and standardization of practices related to transplantation. Still, transplantation is associated with cardiovascular complications, of which post-transplant diabetes mellitus (PTDM) is one of the most important. PTDM increases mortality, which is best documented in patients who have received kidney and heart transplants. PTDM results from traditional risk factors seen in patients with type 2 diabetes mellitus, but also from specific post-transplant risk factors such as metabolic side effects of immunosuppressive drugs, post-transplant viral infections and hypomagnesemia. Oral hypoglycaemic agents are the first choice for the treatment of type 2 diabetes mellitus in non-transplanted patients. However, the evidence on the safety and efficacy of oral hypoglycaemic agents in transplant recipients is limited. The favourable risk/benefit ratio, which is suggested by large-scale and long-term studies on new glucose-lowering drug classes such as glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, makes studies warranted to assess the potential role of these agents in the management of PTDM.
format Online
Article
Text
id pubmed-8290999
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-82909992021-07-26 Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures Schwarzenbach, Marlene Bernhard, Flavia Elena Czerlau, Cecilia Sidler, Daniel World J Transplant Minireviews Solid organ transplantation offers life-saving treatment for patients with end-organ dysfunction. Patient survival and quality of life have improved over the past few decades as a result of pharmacological development, expansion of the donor pool, technological advances and standardization of practices related to transplantation. Still, transplantation is associated with cardiovascular complications, of which post-transplant diabetes mellitus (PTDM) is one of the most important. PTDM increases mortality, which is best documented in patients who have received kidney and heart transplants. PTDM results from traditional risk factors seen in patients with type 2 diabetes mellitus, but also from specific post-transplant risk factors such as metabolic side effects of immunosuppressive drugs, post-transplant viral infections and hypomagnesemia. Oral hypoglycaemic agents are the first choice for the treatment of type 2 diabetes mellitus in non-transplanted patients. However, the evidence on the safety and efficacy of oral hypoglycaemic agents in transplant recipients is limited. The favourable risk/benefit ratio, which is suggested by large-scale and long-term studies on new glucose-lowering drug classes such as glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, makes studies warranted to assess the potential role of these agents in the management of PTDM. Baishideng Publishing Group Inc 2021-07-18 2021-07-18 /pmc/articles/PMC8290999/ /pubmed/34316450 http://dx.doi.org/10.5500/wjt.v11.i7.254 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Schwarzenbach, Marlene
Bernhard, Flavia Elena
Czerlau, Cecilia
Sidler, Daniel
Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
title Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
title_full Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
title_fullStr Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
title_full_unstemmed Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
title_short Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
title_sort chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: a review of literatures
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290999/
https://www.ncbi.nlm.nih.gov/pubmed/34316450
http://dx.doi.org/10.5500/wjt.v11.i7.254
work_keys_str_mv AT schwarzenbachmarlene chancesandrisksofsodiumglucosecotransporter2inhibitorsinsolidorgantransplantationareviewofliteratures
AT bernhardflaviaelena chancesandrisksofsodiumglucosecotransporter2inhibitorsinsolidorgantransplantationareviewofliteratures
AT czerlaucecilia chancesandrisksofsodiumglucosecotransporter2inhibitorsinsolidorgantransplantationareviewofliteratures
AT sidlerdaniel chancesandrisksofsodiumglucosecotransporter2inhibitorsinsolidorgantransplantationareviewofliteratures